Medindia
Medindia LOGIN REGISTER
Advertisement

Quark Pharmaceuticals Poised to Advance Clinical Studies of QPI-1002

Tuesday, January 5, 2010 Research News
Advertisement
First Synthetic siRNA Administered Systemically to Humans for the Prophylaxis of Acute Kidney Injury and Delayed Graft Function

Quark Pharmaceuticals, Inc.

The Ruth Group (investors / media)

Juliana Friedman

Sara Pellegrino / Janine McCargo

+972 89 30 5111

(646) 536-7002 / 7033

[email protected]

[email protected]

[email protected]

Sponsored Post and Backlink Submission


Latest Press Release on Research News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close